Even Dividend Stocks Beating Palantir: Is It Time to Buy?
Palantir remains a topic of debate as dividend-focused peers outperform in choppy markets. Here’s how the latest move...
Find out Which Has Higher Fees Index Fund Or Target Date to prevent hidden costs. This overview covers expense drivers and decision tips.
28,473 articlesPalantir remains a topic of debate as dividend-focused peers outperform in choppy markets. Here’s how the latest move...
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
In May 2026, data show Ethereum as the leading real-world settlement layer amid a growing tokenized-asset market. Inv...
Cloudflare surged about 9% in midday trading after a Scotiabank upgrade. The move comes as AI cloud peers like Oracle...
Markets swing, but smart investors seek durable growth. This article highlights three names with a credible path to m...
Broadcom is edging toward a 52-week peak as AI demand fuels revenue growth and capital returns. Analysts weigh buy, h...
A rising iPhone upgrade cycle is quietly lifting a little-known stock. This article breaks down why the move makes it...
Immersed, a private VR work platform behind the work-from-VR trend, is closing its under-$1 retail round. Early metri...
Palantir (PLTR) sits near $152 after a blowout Q1 2026. Investors weigh whether to buy, hold, or sell Palantir stock ...
When a big investor exits a biotech stock, it rattles the market and raises questions. This deep dive explains the 'f...
The billionaire bill gates' foundation recently remade its public equity lineup, selling its Microsoft stake and conc...
Pershing Square signals a bold bet by leaning into Microsoft as the AI and cloud wave reshapes enterprise tech. The m...